Toronto Dominion Bank
SUPN icon

Toronto Dominion Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

Toronto Dominion Bank’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6
Closed – – 1840
2022
Q1 		$0 Hold
6
– – ﹤0.01% 1950
2021
Q4 		$0 Buy
+6
New +$182 ﹤0.01% 1974

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Toronto Dominion Bank's SUPN Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 6 shares.

Toronto Dominion Bank first reported a position in SUPN in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

  • Toronto Dominion Bank reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 6 Supernus Pharmaceuticals shares in Q2 2022.
  • Toronto Dominion Bank first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Toronto Dominion Bank's Supernus Pharmaceuticals position peaked at $0 in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.